Bryan McMichael compensation by year
Coherus Oncology Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $445,732 | $467,767 | $543,688 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $112,750 | $0 | $0 |
| Option awards | $342,402 | $320,775 | $314,192 |
| Non-equity incentive | $161,834 | $236,828 | $237,697 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $7,500 | $7,500 | $7,500 |
| Total | $1,070,218 | $1,032,870 | $1,103,077 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Coherus Oncology, Inc. DEF 14A filed April 20, 2026, accession 0001104659-26-045251, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Coherus Oncology, Inc. filed document, accession 0001104659-26-045251. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 4,166 | $5,916 | — |
| Option | 160,000 | — | $1.66 |
| Option | 50,000 | — | $1.24 |
| Option | 521 | — | $14.67 |
| Option | 2,813 | — | $10.78 |
| Option | 6,771 | — | $9.87 |
| Option | 7,813 | — | $6.00 |
| Option | 65,105 | — | $3.14 |
| Option | 200,000 | — | $0.95 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Coherus Oncology, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
12 Form 4 lines since the FY2025 proxy (filed April 20, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-29 | Grant or award derivative | — | 30,000 | — | 30,000 |
| 2026-05-29 | Grant or award derivative | — | 100,000 | — | 100,000 |
| 2026-05-29 | Grant or award derivative | — | 25,000 | — | 25,000 |
| 2026-05-29 | Grant or award derivative | — | 15,000 | — | 15,000 |
| 2026-05-29 | Grant or award derivative | — | 25,000 | — | 25,000 |
| 2026-05-29 | Disposition to the issuer derivative | — | 15,000 | — | 0 |
| 2026-05-29 | Disposition to the issuer derivative | — | 25,000 | — | 0 |
| 2026-05-29 | Disposition to the issuer derivative | — | 100,000 | — | 0 |
The 8 most recent of 12 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Coherus Oncology’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Dennis Lanfear | President, Chief Executive Officer and Chairman of the Board of Directors | $2,736,874 |
| Paul Reider | Former Chief Commercial Officer | $1,227,524 |
| Bryan McMichael · this page | Chief Financial Officer | $1,103,077 |
Bryan McMichael's compensation dossier, Coherus Oncology
You have read Bryan McMichael's totals and holdings. The dossier adds each equity grant Coherus Oncology disclosed for Bryan McMichael and Coherus Oncology's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Coherus Oncology compensation record
free company briefThis page is one person within Coherus Oncology's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Coherus Oncology proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Coherus Oncology's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Coherus Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CHRS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.